AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02873416 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Precision Cells
Description: Precision Cells DC cell suspension (1×10\*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision Cell suspension (1-6×109 PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
Study NCT03192735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ApatinibMesylateTablets
Description: Subject will be given ApatinibMesylateTablets 500mg/per day, from day1-day 21,per os; Oxaliplatin for Injection 130mg/m2 /per day，ivgtt，in day1; Gimeracil and Oteracil Porassium Capsules twice times a day,from day1-day 14,per os,and the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; >1.5m2, 60mg every time.A course of treatment need 21days. Every subject need 2-5 courses accrding to tumor assessment by clinician. The last course stop ApatinibMesylateTablets.
Study NCT03937934 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Education
Description: Weekly box of healthy groceries and nutrition education including a recipe, food to make the recipe, extra fruit and vegetables.
Study NCT03041181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 IV Day 1 of each cycle (21 days = 1 cycle)
Study NCT03041181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 IV Day 1 of each cycle (21 days = 1 cycle)
Study NCT03041181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 360 mg IV Day 1 of each cycle (21 days = 1 cycle)
Study NCT03041181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 IV Day 1 and Day 8 of each cycle (21 days = 1 cycle)
Study NCT03041181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 IV Day 1 and Day 8 of each cycle (21 days = 1 cycle)
Study NCT02706912 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VOTA Therapy
Description: During sessions of approximately one hour in duration, participants practice performing virtual activities of daily living (ADLs) using the VOTA system. During this practice, the participant's real-world motion is replicated by an avatar's motion in the virtual world. To complete the activities, participant's must perform a wide range of functional arm movements while interacting with virtual objects. Individuals are asked to perform three such one-hour virtual ADL practice sessions per week over a participation period of approximately eight weeks.
Study NCT02973074 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: OLEOvital
Description: 2sachets with 30mg iron per day for a 4 weeks period
Study NCT02566265 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone High Dose Vaccine
Study NCT02566265 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care/Placebo
Study NCT03041181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 IV Day 1 of each cycle (21 days = 1 cycle)
Study NCT03041181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 IV Day 1 of each cycle (21 days = 1 cycle)
Study NCT04404491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Procedural death 1
Description: 200mg,d1,15,29,43,57,I.V
Study NCT04404491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks in total.
Study NCT04404491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks in total.
Study NCT04404491 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w.
Study NCT04404491 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy
Description: radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w.
Study NCT04404491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo: 200mg,d1,15,29,43,57,I.V
Study NCT03197896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Review prostate cancer information
Study NCT03197896 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Review prostate cancer information
Study NCT02899468 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BrightBrainer Virtual Reality (BBVR) Rehabilitation System
Description: During the active treatment stage (3 sessions per week x 6 weeks), each BBVR therapy session will consist of a series of custom games targeting one or several cognitive domains of executive function, attention, short-term memory, working memory and language comprehension. In addition, the BBVR device incorporates uni- and bi-manual activities by having the subject manipulate hand-held devices, which are programmed to measure in real time the subject's 3D hand movement and index flexion/extension. Therefore, in addition to completing the cognitive tasks, subjects must manipulate virtual hands through a hand-held interface to also enhance visual-motor perception, hand-eye coordination, and upper limb function. In addition, wrist weights can be added to increase upper limb strength training.
Study NCT02899468 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: BrightBrainer Virtual Reality (BBVR) Rehabilitation System
Description: During the active treatment stage (3 sessions per week x 6 weeks), each BBVR therapy session will consist of a series of custom games targeting one or several cognitive domains of executive function, attention, short-term memory, working memory and language comprehension. In addition, the BBVR device incorporates uni- and bi-manual activities by having the subject manipulate hand-held devices, which are programmed to measure in real time the subject's 3D hand movement and index flexion/extension. Therefore, in addition to completing the cognitive tasks, subjects must manipulate virtual hands through a hand-held interface to also enhance visual-motor perception, hand-eye coordination, and upper limb function. In addition, wrist weights can be added to increase upper limb strength training.
Study NCT00684931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging
Description: neuropsychological evaluation and Imaging with magnetic resonance (MRI)
Study NCT00684931 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Imaging
Description: neuropsychological evaluation and Imaging with magnetic resonance (MRI)
Study NCT00960999 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single-fraction stereotactic body radiation therapy (SBRT)
Description: 34 Gy in 1 fraction to the prescription line at the edge of the planning target volume (PTV). The maximum dose must exist within the PTV, and the prescription isodose surface must be ≥ 60% and \< 90% of the maximum dose. 99% of the PTV must receive a minimum of 90% of the prescription dose. The maximum dose to any point ≥ 2 cm away from the PTV in any direction must be at least \< 50% of the prescription dose. The percent of the lungs (excluding PTV) receiving 20 Gy or more must be \< 10%.
Study NCT00960999 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Multiple-fraction stereotactic body radiation therapy (SBRT)
Description: 48 Gy in four 12 Gy fractions to the prescription line at the edge of the planning target volume (PTV). Treatments are given on 4 consecutive calendar days, but at least 18 hours apart. The maximum dose must exist within the PTV, and the prescription isodose surface must be ≥ 60% and \< 90% of the maximum dose. 99% of the PTV must receive a minimum of 90% of the prescription dose. The maximum dose to any point ≥ 2 cm away from the PTV in any direction must be at least \< 50% of the prescription dose. The percent of the lungs (excluding PTV) receiving 20 Gy or more must be \< 10%.
Study NCT02497352 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: flaxseed
Study NCT02497352 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle modification
Study NCT02497352 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: lifestyle modification
Study NCT00327600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imexon
Study NCT00327600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTIC
Study NCT03333278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: Ascorbic acid 1.5g every 6 hours i.v. while in ICU, until shock resolution for a maximum of ten days
Study NCT03333278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiamine
Description: Thiamine 200mg every 12 hours i.v. while in ICU, until shock resolution for a maximum of ten days
Study NCT03333278 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hydrocortisone,
Description: Hydrocortisone 50mg every 6 hours i.v while in ICU, until shock resolution or for a maximum of 7 days, then tapered or stopped.
Study NCT03333278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone,
Description: Hydrocortisone 50mg every 6 hours i.v while in ICU, until shock resolution or for a maximum of 7 days, then tapered or stopped.
Study NCT04493008 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Experimental: Educational session
Description: Each patient will receive educational session consisting of face-to-face interview, administration of posters, brochures and pamphlets.
Study NCT04335006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carelizumab
Description: Participants receive SHR-1210 intravenously (IV)
Study NCT04335006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: administered intravenously every 4-week cycle
Study NCT04335006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: administered intravenously every 4-week cycle
Study NCT04335006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: administered orally every 4-week cycle
Study NCT02951377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise (MDT approach)
Description: Postural or movement exercises of the lower back that aim to centralise and reduce pain intensity.
Study NCT02951377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transforaminal epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%)
Description: An epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%), under guidance of fluoroscopy is used to reduce inflammation at a lumbar spinal nerve root(s).
Study NCT02215460 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FMS full-mouth scaling
Description: Participants received oral hygiene instructions and full-mouth scaling within 24 hours. Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
Study NCT02215460 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: FMS full-mouth scaling
Description: Participants received oral hygiene instructions and full-mouth scaling within 24 hours. Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
Study NCT02215460 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: QS quadrant scaling
Description: Participants received oral hygiene instructions and quadrant scaling in 4 weekly sections. Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
Study NCT02215460 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: QS quadrant scaling
Description: Participants received oral hygiene instructions and quadrant scaling in 4 weekly sections. Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
Study NCT02215460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMS chlorhexidine rinse
Description: Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 60-day use of 0.12% chlorhexidine mouth rinse (15mL/30 seconds/ 2 times a day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
Study NCT02215460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FMS placebo rinse
Description: Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 60-day use of placebo mouth rinse (15mL/30 seconds/ 2 times a day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
Study NCT02215460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMS azithromycin tablets
Description: Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 3-day use of azithromycin tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
Study NCT02215460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FMS placebo tablets
Description: Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 3-day use of placebo tablets (1 tablet/day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
Study NCT02215460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QS azithromycin tablets
Description: Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 3-day use of azithromycin tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
Study NCT02215460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: QS placebo tablets
Description: Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 3-day use of placebo tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
Study NCT02215460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QS chlorhexidine rinse
Description: Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 60-day use of 0.12% chlorhexidine mouth rinse (15mL/30 seconds/2 times a day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
Study NCT02215460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: QS placebo rinse
Description: Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 60-day use of 0.12% placebo mouth rinse (15mL/30 seconds/2 times a day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
Study NCT01362660 — intervention group
Intervention type: OTHER
Intervention: Unintentional exposure in utero
Description: This study will examine post-natal neurologic and cognitive development of infants who may have been exposed to tanezumab or comparator in-utero during the tanezumab clinical program (whether the exposure is through maternal or paternal participation in a tanezumab clinical study).
Study NCT03770637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon RTU
Description: Glucagon RTU is a sterile subcutaneous injectable non-aqueous solution formulation supplied in a vial and administered via syringe.
Study NCT03770637 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a non-active version of Glucagon RTU formulation, containing the same solvent and excipients (i.e., vehicle).
Study NCT00359151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 7 days pre-surgery (excluding day of surgery): 1 celecoxib 200 mg capsule or matching placebo QD; Day of surgery: 2 celecoxib 200 mg capsules or matching placebo within 2 hours prior to surgery, and 1 celecoxib 200 mg capsule or matching placebo following surgery; Post-surgery: starting the day after surgery, 1 celecoxib 200 mg capsule or matching placebo BID for the duration of the study.
Study NCT00359151 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily (QD) for 7 days pre-surgery (excluding the day of surgery); Placebo within 2 hours prior to surgery; and post surgery on the same day of the surgery; Placebo twice daily (BID) following the day of surgery and for the duration of the study.
Study NCT01576653 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fungitell Assay in BAL
Description: Fungitell Assay will be performed in BAL from patients with clinical suspicion of IFI
Study NCT03489174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monthly Pregnancy Screening
Description: Pregnancy test will be administered once per month during weekly urine testing for drug levels.
Study NCT03489174 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care.
Study NCT04849936 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Testing Fecal Biomarkers In Comparison To Endoscopic Examination With Confocal Laser Endomicroscopy
Description: Patients, who were examined during a routine diagnostics, should submit an extra morning stool sample up to two weeks before or after the gastroscopy and/or coloscopy to generate the data of the fecal biomarker mentioned above.
Study NCT04068259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-4547
Description: PBI-4547 tablet
Study NCT04068259 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet
Study NCT05210218 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cinnamomum cassia (CC) and Withania somnifera (WS) (300 mg+150mg, respectively)
Description: The study product, in a capsule formulation, was made by the extract of Cinnamomum cassia (CC) and Withania somnifera (WS) (300 mg+150mg, respectively) (Nutrintech Ltd., London, UK)
Study NCT05210218 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: cellulose
Study NCT01041352 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laryngeal mask
Description: LMA Proseal
Study NCT01041352 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endotracheal tube
Description: Unomedical endotracheal tube
Study NCT01561209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitryptiline
Description: Amitryptiline 5 mg before bedtime for 2 months
Study NCT01561209 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill~1 before bedtime
Study NCT02529813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02529813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT02529813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02529813 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Description: Given IV
Study NCT02742623 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY 59-7939)
Description: Treatment with rivaroxaban for DVT and/ or PE and/ or prevention of recurrent DVT and PE according to local label
Study NCT01581151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant
Description: Patients will receive a Dexamethasone implant and ranibizumab, as needed. A comparison will be made between ranibizumab and Dexamethasone implant with rescue ranibizumab.
Study NCT01581151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monthly Ranibizumab
Description: 30 days between treatments
Study NCT02548260 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Syndactyly without compression
Description: three week relative immobilization by syndactyly
Study NCT02548260 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Syndactyly with compression
Description: three week relative immobilization by syndactyly and compression
Study NCT02548260 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rigid splint without compression
Description: three week rigid immobilization by splint
Study NCT02548260 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rigid splint with compression
Description: three week rigid immobilization by splint and compression
Study NCT00816686 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-16M18
Description: IV Infusion
Study NCT01208441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Study NCT01208441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097